ストックスクリーナーアプリを入手
1.54
0.00%
0.00
プレマーケット:
1.56
0.02
+1.30%
前日終値:
$1.54
開ける：
$1.49
24時間の取引高:
450.98K
Relative Volume:
0.34
時価総額：
$4.63M
収益：
$129.20K
当期純損益:
$-7.44M
株価収益率:
-0.1376
EPS:
-11.19
ネットキャッシュフロー:
$-8.62M
1週間 パフォーマンス:
+1.32%
1か月 パフォーマンス:
-1.28%
6か月 パフォーマンス:
-77.35%
1年 パフォーマンス:
-85.53%
1日の値動き範囲:
$1.44
$1.56
1週間の範囲:
$1.44
$1.5807
52週間の値動き範囲:
$1.41
$18.72
Sonnet Biotherapeutics Holdings Inc Stock (SONN) Company Profile
名前
Sonnet Biotherapeutics Holdings Inc
セクター
電話
609-375-2227
住所
100 OVERLOOK CENTER, PRINCETON, NJ
SONN を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SONN
Sonnet Biotherapeutics Holdings Inc
|
1.54 | 4.63M | 129.20K | -7.44M | -8.62M | -11.19 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Sonnet Biotherapeutics Holdings Inc (SONN) 最新ニュース
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to Evaluate Combination of SON-1010 with Trabectedin in Certain Sarcomas - Defense World
Sonnet BioTherapeutics begins trial combining SON-1010, trabectedin - MSN
Sonnet BioTherapeutics Expands Phase 1 Study for SON-1010 - TipRanks
Sonnet BioTherapeutics Expands Phase 1 SB101 Trial to - GlobeNewswire
Why Sonnet BioTherapeutics (SONN) Shares Are Down 19% Today - MSN
Sonnet BioTherapeutics (NASDAQ:SONN) Stock Quotes, Forecast and News Summary - Benzinga
Sonnet BioTherapeutics Announces Release of the Next CEO Corner Segment - GlobeNewswire
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Corporate UpdateOn December 17, 2024, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company developing targeted immunotherapeutic drugs, released it - Defense World
Insights into Sonnet BioTherapeutics Q4 Earnings - Benzinga
Sonnet BioTherapeutics Reports Fiscal Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Sonnet BioTherapeutics Slashes Operating Costs 37% in FY2024, Advances Cancer Drug Pipeline - StockTitan
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Sonnet BioTherapeutics (NASDAQ: SONN) Announces $3.9 Million Registered Direct Offering and Private PlacementPrinceton, New Jersey, December 9, 2024 – Sonnet BioTherapeutics Holdings, Inc. (SONN), a clinical-stage company focusing on targeted i - Defense World
Sonnet BioTherapeutics (NASDAQ: SONN) Reports Positive Safety Data in SON-1010 Monotherapy Dose Escalation Trial - Defense World
Sonnet BioTherapeutics reports progress in cancer trial By Investing.com - Investing.com Nigeria
Sonnet BioTherapeutics reports progress in cancer trial - Investing.com India
Sonnet BioTherapeutics Announces $3.9 Million Registered - GlobeNewswire
Sonnet BioTherapeutics Secures $3.9M Strategic Financing Deal Through Mixed Securities Offering - StockTitan
Sonnet BioTherapeutics Announces Topline Safety Data - GlobeNewswire
Sonnet Bio's Cancer Drug Shows Promise: 48% Disease Control, One Patient's Tumor Shrinks 45% in Phase 1 Trial - StockTitan
Sonnet BioTherapeutics reports advances in cancer treatment drug By Investing.com - Investing.com Canada
Sonnet BioTherapeutics reports advances in cancer treatment drug - Investing.com India
Sonnet BioTherapeutics Announces Publication Detailing the - GlobeNewswire
Sonnet BioTherapeutics Unveils Breakthrough Cancer Drug Delivery System in Major Publication - StockTitan
Sonnet BioTherapeutics Holdings (STU:H3D) Financial Strengt - GuruFocus.com
Comfort Systems USA (FIX-N) QuotePress Release - The Globe and Mail
Sonnet BioTherapeutics’ $5 Million Common Stock Offering - Global Legal Chronicle
Sonnet BioTherapeutics Holdings (STU:H3D) Change In Receiva - GuruFocus.com
Sonnet BioTherapeutics Releases Virtual Investor ‘”What this Means” Segment - GlobeNewswire
Sonnet BioTherapeutics Secures Crucial Patent for Novel Cancer Immunotherapy Pipeline | SONN Stock News - StockTitan
Sonnet BioTherapeutics (NASDAQ: SONN) Announces Issuance of U.S. Patent for Novel Immunotherapeutic Drug Candidates - Defense World
Sonnet BioTherapeutics secures US patent covering two drug candidates - Pharmaceutical Technology
Sonnet BioTherapeutics secures patent for cancer drug candidates By Investing.com - Investing.com Australia
SONN stock touches 52-week high at $9.9 amid market optimism - Investing.com Australia
Sonnet BioTherapeutics Prices of $5.0 Million Underwritten Public Offering - citybiz
Sonnet BioTherapeutics Announces Pricing of $5.0 Million - GlobeNewswire
Sonnet BioTherapeutics sets $5 million stock offering - Investing.com India
Sonnet BioTherapeutics sets $5 million stock offering By Investing.com - Investing.com UK
Sonnet BioTherapeutics Raises $5M in Stock Offering with Warrant Coverage | SONN Stock News - StockTitan
Sonnet BioTherapeutics secures patent for cancer drug candidates - Investing.com India
U.S. Stock market: SONN(+86.46%), DataChat(+50.28%), Cytek Biosciences(+30.51%) among the top gainers during early trading - Business Upturn
Sonnet BioTherapeutics Secures Patent for Cancer Drugs - TipRanks
Sonnet BioTherapeutics Announces Issuance of U.S. Patent - GlobeNewswire
Sonnet BioTherapeutics Secures Key Patent for Novel Cancer Immunotherapy Drugs | SONN Stock News - StockTitan
Sonnet stock tumbles 22% in wake of proposed offering filing - MSN
(SONN) On The My Stocks Page - Stock Traders Daily
Dow Jumps Over 300 Points; ON Semiconductor Earnings Top ViewsHealthcare Triangle (NASDAQ:HCTI) - Benzinga
Sonnet Biotherapeutics Holdings Inc (SONN) 財務データ
収益
当期純利益
現金流量
EPS
4.81%
大文字化:
|
ボリューム (24 時間):